Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 10Prostatic Neoplasms 7Lung Neoplasms 6Recurrence 4Multiple Myeloma 4Lymphoma, B-Cell 4Lymphoma 4Colorectal Neoplasms 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Urologic Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia 2Glioblastoma 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Vasculitis 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1

Interventions

tazemetostat 1etoposide phosphate 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × 90 days × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡